Continuous vindesine infusion in advanced head and neck cancer

Am J Clin Oncol. 1983 Jun;6(3):301-4. doi: 10.1097/00000421-198306000-00008.

Abstract

Sixteen patients with advanced squamous cell carcinoma of the head and neck were treated with a 48-hour I.V. vindesine infusion. The dosage was 3 mg/m2/48 hours every 2 weeks. Toxicity consisted of leukopenia, paresthesias, and phlebitis. Major objective responses were seen in four patients (one CR, three PR), with a median duration of 4 months.

MeSH terms

  • Aged
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Squamous Cell / drug therapy*
  • Drug Evaluation
  • Female
  • Head and Neck Neoplasms / drug therapy*
  • Humans
  • Infusions, Parenteral
  • Male
  • Middle Aged
  • Vinblastine / administration & dosage
  • Vinblastine / analogs & derivatives*
  • Vinblastine / therapeutic use
  • Vindesine

Substances

  • Antineoplastic Agents
  • Vinblastine
  • Vindesine